Almirall SA, founded in 1943 and headquartered in Barcelona, Spain, is a global biopharmaceutical company dedicated to the research, development, and commercialization of innovative dermatology products. The company focuses on addressing unmet medical needs in skin diseases through its robust portfolio, which includes prescription drugs and consumer health products.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| ALMSM 2.13% 2026-09-30 EURAlmirall SA | Spain | 2026-09-30 | 2.125 | 2.04 |
| ALMSM 2.13% 2026-09-30 EURAlmirall SA | Spain | 2026-09-30 | 2.125 | 2.04 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Almirall began issuing bonds in 2015 to bolster its financial structure and expand its operations, notably launching a €300 million bond that featured a 5-year maturity. In recent years, the company has seen varying yields on its debt instruments, generally aligning with industry trends but occasionally outperforming peers in stability during market fluctuations. Noteworthy was the issuance in 2021, which aimed to finance strategic acquisitions and R&D projects, reflecting Almirall's commitment to growth in the dermatology sector.